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INTRODUCTION
Breast cancer accounts for 32%of female cancer and is
responsible for 19% of the cancer related deaths in
women. In India [1, 2], it is second only to Ca cervix.
The annual incidence of ca breast in India is 20.1 per
1, 00,000 women [3].
The prognosis of ca breast is difficult to express, but
sen nel lymph node mapping has been a valuable tool
in decreasing the morbidity that ensues breast surger-
ies especially modified radical mastectomy [4]. Sen nel
lymph node (SLN) mapping [5,6,7] is a promising new
medical technique that is gaining popularity before the
medical community has had me to provide adequate
training and put the procedure into prac ce in a safe
and organised manner. SLN mapping [8,9] is minimally
invasive and can reduce morbidity and cost.
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It is able to provide the pathologist with a limited num-
ber of lymph nodes to allow a focussed analysis. It is
the most accurate detec on tool used in staging of
breast cancer [6].
Sen nel lymph node (SLN) mapping and dissec on is a
more sensi ve and accurate technique for nodal evalu-
a on and has been applied to staging of axillary lymph
nodes in pa ents with breast cancer, providing prog-
nos c informa on, with less surgical morbidity than
with axillary lymph node dissec on (ALND) [10, 11].
In theory, a malignancy from primary breast cancer
spreads to axillary lymph nodes (AXLNs) and progresses
in an orderly fashion from primary tumour to the sen -
nel lymph node and subsequently to the other AXLNs
[12-14]; therefore, SLN is the node most likely to con-
tain metasta c tumour cells. If the SLN is not involved,
then other ALND’s should have a very low likelihood to
be affected by metastasis [12, 15, 16]. However, sen -
nel lymph node biopsy requires valida on by a backup
ALND in a defined series of cases before becoming
standard prac ce, to establish individual and ins tu-
onal success rates and the frequency of false nega-
ve.
Sen nel lymph node biopsy may help in determining
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which pa ent can avoid axillary lymph node dissec on
and consequent morbidity due to unnecessary ALND.
Sen nel node biopsy results in a significant reduc on in
physical and psychological morbidity when compared
to axillary clearance. Such favourable consequences
seem to apply equally in short and long term evalua-
on.
However at present there is no standard protocol for
the localiza on for the histological of the sen nel
lymph nodes. On this background, the present study
has been undertaken.
Aims & Objec ves
To study the mapping of lympha c passage of sen nel
lymph node in pa ents of carcinoma of breast pre-
sen ng in Oncology Department, Pravara Rural Hospi-
tal, Loni. To study the pathological correla on of SLNB
and ALND in pa ents of carcinoma of breast presen ng
in Oncology Department, Pravara Rural Hospital, Loni.
MATERIALS AND METHODS
Study design: Observa onal study
Ethics approval: The study was ini ated a er Ethics
commi ee approval and informed consent was taken
from the par cipants.
Study period: The study was undertaken during No-
vember 2015 to October 2017
Study loca on: Department of Oncology Department,
Pravara Rural Hospital, Loni.
Sample size: Fi y were par cipated
Sample selec on: It included 50 breast carcinoma pa-
ents sa sfying the inclusion and exclusion criteria.
Inclusion criteria: Pa ents presen ng with palpable
breast carcinoma without clinically palpable or suspi-
cious axillary lymph nodes, poten ally curable breast
carcinoma (T1, T2 tumours) that were undergoing
ALND and willing to par cipate in the study were in-
cluded in the study.
Exclusion criteria: Pa ents with prior axillary opera-
ons, large & locally advanced invasive breast cancers,
ductal carcinoma in situ, prior breast surgery, prior
chemotherapy, distant metastases and pregnant wom-
en were excluded from the study.
Pa ents with poten ally curable breast carcinoma who
were undergoing ALND as part of their standard treat-
ment were evaluated.
Methodology
Sen nel lymph nodes were iden fied by the methylene
blue dye. The method involves injec ng methylene
blue dye peritumorally or subdermally or periareolar
region. During the opera on the blue dye [5,7, 10]  was
injected in the breast tumor to help iden fy the first
node. Sen nel lymph node was iden fied and send for
histo-pathological examina on seperately. Standard
axillary dissec on was done a er mastectomy and rest
of the axillary lymph nodes were sent for histo patho-
logical examina on along with sen nel lymph node.
In view of the ins tu onal protocol ALND was per-
formed in all pa ents though tracing was done for sen-
nel nodes.
The sen nel lymph nodes iden fied and the remaining
axillary lymph nodes were examined by standard histol-
ogy. The fibrous-fa y ssue surrounding the lymph
node was carefully removed without breaking the cap-
sule.The lymph node was then bisected along its major
axis. Both halves were embedded in medium used for
freezing the ssues with cut surfaces up and ssues
frozen in isopentane cooled with liquid nitrogen.
Lymph nodes less than 5 mm were embedded and fro-
zen uncut. If two or more sen nel lymph nodes were
sent all were examined.
Tumours were classified histologically according to the
world health organisa on histological classifica on of
breast tumours as modified by Rosan and Obermann
[17]. The other axillary lymph nodes were isolated from
fat ssue without freezing or preserva on and exam-
ined by standard technique. Lymph nodes greater than
0.5 cm were bisected lymph nodes smaller than 0.5 cm
were fixed and embedded uncut. Three sec ons were
obtained from each lymph node at different levels (100
-500 um apart) and stained with HE.
The sensi vity and specificity of these tests were calcu-
lated according to the following formula:
Sensi vity= True Posi ves / True Posi ves + False Nega-
ves
Specificity = True Nega ves / True Nega ves +False
Posi ves
RESULTS
50 women underwent intra opera ve lympha c map-
ping and sen nel lymphadenectomy immediately be-
fore modified radical mastectomy or breast con-
serva ng surgical treatment of primary breast carcino-
ma. The age of pa ents ranged from 35 to 80, with
more number of pa ents in the age group of 41 to 50
years.
Of the 26 pa ents whose had clinically palpable, axil-
lary lymph node, 13 (50%) had histologically nega ve
nodes; of 14 pa ents with clinically nega ve axillary
nodes, 11 (78.57%) had histological evidence of axillary
metastasis.
Figure 1: Age distribution of patients with carcino-
ma breast
With respect to grading of tumour, 32 pa ents (64%)
had T2, while the rest had T1 grade carcinoma. Of the
50 pa ents, 26 (52%) were post menopausal while 24
were pre menopausal.
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Figure 2: Histological correla on between sen nel
lymph node and other axillary lymph nodes.
The blue staining sen nel lymph node was iden fied in
30 of 50 (60%) procedures. Of the 30 pa ents in whom
SLN was iden fied, 1 (3.33%) had histologically nega-
ve nodes and 29(96.66%) had histologically posi ve
nodes; of 20 pa ents who had nega ve sen nel nodes,
19(95%) had histologically nega ve evidence of axillary
metastasis, while 1 (5%) showed histologically posi ve
evidence of axillary metastasis.
The sen nel node accurately iden fied axillary nodal
status in 30 of 50 cases (60%). In 1 of 50 cases (2%), the
sen nel node was histologically nega ve, i.e., no tumor
was iden fied in the sen nel node, but at least one non
sen nel node harbored metastasis.
Of the total sen nel lymph nodes examined, 29 cases
were histologically posi ve, 1 case was histologically
nega ve. Thus, it was highly unlikely that uptake of dye
by an involved node was a result of chance alone.
The sensi vity of sen nel lymph node status with com-
parison to the gold standard, ie, histopathology report,
was 96.6% while the specificity was 95%. The overall
posi ve and nega ve predic ve values were 96.67%
and 95%, respec vely. The overall accuracy of the tests
done by me was found to be 47.5%.
Table 1: Complica ons following axillary lymph node
dissec on
Complica on a er the axillary lymph node dissec on
was seen in 17 pa ents (34%), most common of which
was infec on.
DISCUSSION
ALND remains the standard of care for pa ents with
Complications No of cases
Immediate Wound dehiscence 2
Infection 7
Haemorrhage 1
Lymphatic collection 3
Late Lymphedema 1
Neuralgia 2
Restricted movement 1
Total 17
locally advanced breast cancer or inflammatory breast
cancer, for those with a posi ve SLN who are planned
for mastectomy, and for those with a posi ve sen nel
node a er neoadjuvent chemotherapy.
SLNB is less invasive than ALND and facilitates more
accurate staging but as per our ins tu onal protocol all
pa ents underwent ALND a er ini al sen nel node
tracing. Research has indicated that 25% of pa ents
with sen nel node micro metastases had residual axil-
lary disease whereas pa ents with a single sen nel
node micro metastasis and more than four disease-free
sen nel nodes were unlikely to have axillary disease
[8,9,18].
Determina on of axillary nodal status is essen al for
the staging of breast cancer. However, the   extent   of
axillary    dissec on   required   for accurate staging is
controversial. Total dissec on of the axilla has the high-
est morbidity, but offers the greatest staging accuracy.
The accuracy of limited dissec ons or sampling proce-
dures is unclear par ally because these procedures
o en are ill defined and par ally because of the meth-
ods used to evaluate their accuracy. Differences in stag-
ing techniques are well defined by Kinne [19].
Forrest et al [20]. demonstrated an 8% false-nega ve
rate in specimens with three to four lymphnodes, and
Steele et al [21] suggested that removal of at least four
nodes from the lower axillary fat pad near the tail of
the breast was as accurate as ALND.
Giuliano’s [5, 13, 14, 20] work reflects the developmen-
tal stage of blue dye SLN mapping for breast cancer,
with successful SLN localiza ons increasing from 65%
to 93% over a personal experience of hundreds of cas-
es. Most false-nega ve results occurred in earlier pa-
ents.
Krag et al’s [22, 23] mul center valida on study, 15
which reports on isotope-guided SLN biopsy for breast
cancer as performed by 11 surgeons at 11 different
ins tu ons, is more discouraging. Although SLNs were
found in 93% of 443 cases (range 82% to 98%), false-
nega ve results occurred in 11.4% of 114 node-posi ve
cases (range 0% to 28.6%). The false nega ve percent-
age is much lower in our study. In the present study, of
the 30 pa ents in whom SLN was iden fied, 1(3.33%)
had histological nega ve nodes and 29(96.66%) had
histological posi ve nodes; of 20 pa ents who had neg-
a ve sen nel nodes, 19(95%) had histological nega ve
evidence of axillary metastasis, while 1(5%) showed
histological posi ve evidence of axillary metastasis.
This varia on could be due to difference in the popula-
on or a smaller sample size. Also in these studies, suc-
cessful SLN localiza on was more frequent for high-
volume surgeons, as expected, but the false-nega ve
rate was unrelated to surgical experience: indeed, one
of the three highest-volume surgeons also had the
highest false-nega ve rate (28.6%).
The false nega ve rate for SLN surgery ranges from 0 to
10% as reported in NSABP B-32 trial [24]. Pa ents who
present with clinical palpable lymph nodes should be
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evaluated with axillary ultrasonography and FNAB of
the nodes. If axillary metastasis is confirmed pa ents
can procede directly to standard axillary lymph node
dissec on or be considered for neoadjuvant chemo-
therapy. If axillary metastasis is not confirmed by FNA
biopsy then pa ents can procede to SLN surgery for
staging.
Fisher et al [25, 26]  have suggested that ALND offers
no survival advantage and that level I and II dissec on
would accurately stage most pa ents with breast can-
cer. In this study, the majority of breast cancer pa ents
with axillary disease had metastases limited to level I
nodes. Because the survival benefit of ALND is unclear,
the necessary extent of axillary dissec on may be de-
termined best by staging accuracy and local control.
CONCLUSION
The SLN accurately reflects the status of axillary lymph
nodes in most pa ents with breast cancer, and for
those with early stage disease it is rapidly emerging as
an alterna ve to conven onal axillary dissec on. Alt-
hough SLNB for early breast cancer may be considered
state of the art in experienced hands, informa on on
creden aling for this new procedure is scarce. The ex-
perience indicates that intraopera ve lympha c map-
ping can accurately iden fy the sen nel node i.e., the
axillary lymph node most likely to contain breast cancer
metastases in some pa ents. The technique could en-
hance staging accuracy and with further refinements
and experience, might alter the role of ALND.
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